Matthew Weitzman

Prof. Dr. Matthew Weitzman

1. Division of Protective Immunity and Division of Cancer Pathobiology, Children’s Hospital of Philadelphia, Philadelphia, PA 19104, USA
+1
orcid

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2008 in Cell
Verified
Journal Article
Closed access
Renate KönigRenate König
Renate König
YZYingyao Zhou
Yingyao Zhou
DEDaniel Elleder
Daniel Elleder
TDTracy L. Diamond
Tracy L. Diamond
GBGhislain M.C. Bonamy
Ghislain M.C. Bonamy
SCSumit K. Chanda
Sumit K. Chanda

1 June 2005 in Annual Review of Biochemistry
Verified
Journal Article
Closed access
IVInder M. Verma
Inder M. Verma
Matthew WeitzmanMatthew Weitzman
Matthew Weitzman
▪ Abstract Broadly defined, the concept of gene therapy involves the transfer of genetic material into a cell, tissue, or whole organ, with the goal of curing a disease or at least improving the clinical status of a patient. A key factor in the success of gene therapy is the development of delivery systems that are capable of efficient gene transfer in a variety of tissues, without causing any associated pathogenic effects. Vectors based upon many different viral systems, including retroviruses, lentiviruses, adenoviruses, and adeno-associated viruses, currently offer the best choice for efficient gene delivery. Their performance and pathogenicity has been evaluated in animal models, and encouraging results form the basis for clinical trials to treat genetic disorders and acquired diseases. Despite some initial success in these trials, vector development remains a seminal concern for improved gene therapy technologies.

1 July 2002 in Nature
Verified
Journal Article
Closed access
PDF file
TSTravis H Stracker
Travis H Stracker
CCChristian T. Carson
Christian T. Carson
Matthew WeitzmanMatthew Weitzman
Matthew Weitzman

15 December 2003 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
CCChristian T. Carson
Christian T. Carson
RSRachel A. Schwartz
Rachel A. Schwartz
TSTravis H Stracker
Travis H Stracker
CLCaroline E. Lilley
Caroline E. Lilley
DLDarwin V. Lee
Darwin V. Lee
Matthew WeitzmanMatthew Weitzman
Matthew Weitzman
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.

22 July 2010 in FEBS Letters
Verified
Journal Article
Closed access
BLBrandon J. Lamarche
Brandon J. Lamarche
NONicole I. Orazio
Nicole I. Orazio
Matthew WeitzmanMatthew Weitzman
Matthew Weitzman

1 January 1996 in Journal of Virology
Verified
Journal Article
Closed access
KFK J Fisher
K J Fisher
GGG P Gao
G P Gao
Matthew WeitzmanMatthew Weitzman
Matthew Weitzman
RDR DeMatteo
R DeMatteo
JBJ F Burda
J F Burda
JWJ M Wilson
J M Wilson
Adeno-associated virus is an integrating DNA parvovirus with the potential to be an important vehicle for somatic gene therapy. A potential barrier, however, is the low transduction efficiencies of recombinant adeno-associated virus (rAAV) vectors. We show in this report that adenovirus dramatically enhances rAAV transduction in vitro in a way that is dependent on expression of early region 1 and 4 (E1 and E4, respectively) genes and directly proportional to the appearance of double-stranded replicative forms of the rAAV genome. Expression of the open reading frame 6 protein from E4 in the absence of E1 accomplished a similar but attenuated effect. The helper activity of adenovirus E1 and E4 for rAAV gene transfer was similarly demonstrated in vivo by using murine models of liver- and lung-directed gene therapy. Our data indicate that conversion of a single-stranded rAAV genome to a duplex intermediate limits transduction and usefulness for gene therapy.